Zai Lab Limited – American Depositary Shares (NASDAQ:ZLAB) Sellers Decreased Their Shorts By 0.01%

June 29, 2018 - By Alma Kearns

It was registered a decrease on Zai Lab Limited – American Depositary Shares (NASDAQ:ZLAB)’s shares shorted with 0.01%. FINRA issued in June ZLAB’s total 1.85 million shares shorted. The 1.86M previous shares are down with 0.01%. Previous ZLAB’s position will need 31 days to recover. It has 60,300 average volume. Zai Lab Limited – American Depositary Shares’s shares shorted float is 65.15%.

The stock increased 1.09% or $0.2486 during the last trading session, touching $23.0386.Currently Zai Lab Limited is after 0.00% change in last June 29, 2017. ZLAB has 11,052 shares volume. ZLAB underperformed the S&P500 by 12.57%.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China.The company has $1.17 billion market cap. The Company’s drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus.Currently it has negative earnings.

More recent Zai Lab Limited (NASDAQ:ZLAB) news were released by Nasdaq.com, Benzinga.com and Globenewswire.com. The first one has “Zai Lab Announces Dosing of First Patient in Phase 3 China Registration Trial of ZL-2306 (niraparib) for First-Line …” as a title and was released on June 29, 2018. The next is “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” on June 03, 2018. And last was released on June 05, 2018, called “Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: